BCL-2 family protein deregulation in MM and the ability of IAP antagonists to activate caspases directly, thus bypassing BCL-2/MCL-1 [18], make such compound attractive candidates in this disease. This evidence concerns the gene BCL2 and Miyoshi myopathy.